Monoclonal Antibody Therapeutics Market Analysis (2020-2027)
Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017, the U.S. Food & Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma, who have received two prior therapies. These factors are expected to support growth of the market over the forecast period.
Market Dynamics
Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.
Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2019 in Europe.
Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Key features of the study:
· This report provides in-depth analysis of the global monoclonal antibodies market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
· It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
· This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
· It profiles key players in the global monoclonal antibodies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
· Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
· Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future launches, market expansion, and marketing tactics
· The global monoclonal antibodies market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
· Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibodies market
Detailed Segmentation:
· Global Monoclonal Antibodies Market, By Source:
o Human
o Chimeric
o Murine
o Humanized
· Global Monoclonal Antibodies Market, By Application:
o Cancer
o Autoimmune Disease
o Hematological Disease
o Infectious Disease
o Others
· Global Monoclonal Antibodies Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
· Global Monoclonal Antibodies Market, By Region:
o North America
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ U.S.
§ Canada
o Latin America
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ Brazil
§ Mexico
§ Argentina
§ Rest of Latin America
o Europe
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Russia
§ Rest of Europe
o Asia Pacific
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ China
§ India
§ Japan
§ Australia
§ South Korea
§ ASEAN
§ Rest of Asia Pacific
o Middle East
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country:
§ GCC
§ Israel
§ Rest of Middle East
o Africa
§ By Source:
§ Human
§ Chimeric
§ Murine
§ Humanized
§ By Application:
§ Cancer
§ Autoimmune Disease
§ Hematological Disease
§ Infectious Disease
§ Others
§ By Distribution Channel:
§ Hospital Pharmacies
§ Retail Pharmacies
§ Online Pharmacies
§ By Country/Region:
§ South Africa
§ Central Africa
§ North Africa
· Company Profiles
o Pfizer Inc.*
§ Company Overview
§ Product Portfolio
§ Financial Performance
§ Key Highlights
§ Market Strategies
o Novartis AG
o Bayer AG
o Sanofi S.A.
o Hoffmann-La Roche AG
o Eli Lilly and Co.
o Merck & Co., Inc.
o GlaxoSmithKline Plc.
o AbbVie Inc.
o Bristol-Myers Squibb
o Regeneron Pharmaceuticals Inc.
https://www.coherentmarketinsights.com/insight/request-sample/2403
https://www.coherentmarketinsights.com/insight/request-pdf/2403
Click here to buy:https://www.coherentmarketinsights.com/insight/buy-now/2403
CMI Services:https://www.coherentmarketinsights.com/services
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
· Customized Market Research Services
· Industry Analysis Services
· Business Consulting Services
· Market Intelligence Services
· Long term Engagement Model
· Country Specific Analysis
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email :[email protected]
Reference/Source: https://www.coherentmarketinsights.com/market-insight/monoclonal-antibody-therapeutics-market-2403